Another option to enhance antigen presentation and to overcome resistance to HER2 mAb therapies may be activation of antibody-dependent cell phagocytosis (ADCP) by TAMs of HER2+ BC patients with poor trastuzumab response. This evidence concerns the gene ERBB2 and breast cancer.